Current management of T1DM remains primarily symptomatic and relies on lifelong exogenous insulin replacement delivered via multiple daily injections or continuous sub-cutaneous insulin infusion systems, frequently combined with real-time continuous glucose monitoring (CGM) and hybrid closed-loop automated insulin delivery (AID) systems such as the Medtronic MiniMed 780G and Tandem t:slim X2 with Control-IQ and Dexcom G7 integration [7,8]. Here, INS is linked to type 1 diabetes mellitus.